What are the Curaçao criteria for diagnosing Hereditary Hemorrhagic Telangiectasia (HHT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Curaçao Criteria for Hereditary Hemorrhagic Telangiectasia

The Curaçao criteria are four clinical diagnostic criteria for HHT: (1) spontaneous and recurrent epistaxis, (2) multiple telangiectasias at characteristic sites (lips, oral cavity, fingers, nose), (3) visceral arteriovenous malformations (pulmonary, hepatic, cerebral, spinal, or gastrointestinal), and (4) a first-degree relative with HHT—with three criteria confirming definite diagnosis, two indicating possible HHT, and fewer than two making HHT unlikely. 1, 2

Diagnostic Interpretation Algorithm

Definite HHT (3 or 4 criteria present)

  • The positive predictive value of meeting three criteria is 100%, meaning genetic testing will confirm an HHT mutation in essentially all cases. 3
  • Proceed directly to organ-specific screening without requiring genetic confirmation 2
  • 90.3% of mutation-positive patients meet definite clinical criteria 3

Possible HHT (2 criteria present)

  • Genetic testing is essential in this group, as only 32.7% will have an HHT-causing mutation. 3
  • Target mutations in ENG, ACVRL1, and SMAD4 genes, which identify causative mutations in 97% of clinically definite cases 2
  • If genetic testing is positive, initiate full organ screening protocols 2

Unlikely HHT (0-1 criteria present)

  • The negative predictive value of an unlikely diagnosis is 97.7%, effectively ruling out HHT. 3
  • Only 0.5% of mutation carriers present with fewer than two criteria 3

Detailed Criteria Specifications

Criterion 1: Epistaxis

  • Must be both spontaneous (not trauma-induced) and recurrent 1, 4
  • Occurs in more than 90% of adults with HHT 2

Criterion 2: Telangiectasias

  • Must be multiple lesions 1
  • Located at characteristic sites: lips, oral cavity, fingers, and nose 1, 5
  • These lesions have age-related expression, often developing in the 5th decade of life 5

Criterion 3: Visceral Lesions

  • Includes pulmonary arteriovenous malformations 1, 4
  • Hepatic arteriovenous malformations (found in 44-74% of HHT patients) 1
  • Cerebral or spinal arteriovenous malformations 1, 5
  • Gastrointestinal telangiectasias 1, 4

Criterion 4: Family History

  • Must be a first-degree relative (parent, sibling, or child) 1, 2
  • The relative must meet Curaçao criteria for HHT diagnosis 1
  • Given autosomal dominant inheritance, each child has 50% chance of inheriting the disease 2

Critical Clinical Pitfalls

Phenotypic variation is substantial even within families carrying the same mutation, so absence of symptoms in relatives does not exclude HHT. 6

Age-dependent penetrance means younger patients may not yet manifest all criteria—epistaxis typically appears first, followed by telangiectasias decades later. 2, 5

Gender influences hepatic involvement, with females showing 2-4.5 times higher rates of hepatic vascular malformations. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnostic Approach for Hereditary Hemorrhagic Telangiectasia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Hereditary hemorrhagic telangiectasia: how accurate are the clinical criteria?

American journal of medical genetics. Part A, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.